Charles Sherr, MD, PhD

Charles J. Sherr, MD, PhD

Member, St. Jude Faculty
Chair, Tumor Cell Biology
Investigator, Howard Hughes Medical Institute
Herrick Foundation Chair


Tumor Cell Biology

Contact Information

Charles Sherr, MD, PhD
Tumor Cell Biology
MS 350, Room D-5006D
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678


MD - New York University School of Medicine
PhD - New York University Graduate School of Arts and Sciences

Honors & Awards

Research Interests

Our laboratory has traditionally focused on the mechanisms by which mitogens relay proliferative signals that affect progression through the mammalian cell division cycle. Current projects emphasize the rate limiting effects of cyclins and cyclin-dependent kinases (CDKs) on G1 phase progression; the role of CDK inhibitors (INK4 and Cip/Kip proteins) in cell cycle control, organismal development, and tumorigenesis in vivo; the activity of particular tumor suppressors, including INK4A-ARF, p53, and RB, in cell line establishment, senescence, stem cell biology, and protecting against oncogenic insults. Postdoctoral fellows and graduate students receive joint supervision by Drs. Roussel and Sherr in a multi-disciplinary program that seeks to maximize trainees’ abilities to successfully perform novel and speculative experiments.


Selected Publications

Sherr CJ. Ink4-Arf locus in cancer and aging. WIRES Dev Biol published online Feb 28, 2012. DOI 10.1002/WDEV40

Churchman ML, Roig I, Jasin M, Keeney S, Sherr CJ. Expression of Arf tumor suppressor in spermatogonia facilitates meiotic progression in male germ cells. PLoS Genetics Jul 7(7):e1002157, 2011.

Treanor LM, Volanakis EJ, Zhou S, Lu T, Sherr CJ, Sorrentino BP. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood March 22, 2011.

Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood January 24, 2011.

Volanakis EJ, Sherr CJ. Developmental strategies for evasion of Arf tumor suppression. Cell Cycle 9:14-15, 2010.

Volanakis EJ, Williams RT, Sherr CJ. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Blood 114:4451-4459, 2009.

Gromley A, Churchman ML, Zindy F, Sherr CJ. Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proc Natl Acad Sci USA 106: 6285-6290, 2009.

Williams RT and Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. Cold Spring Harbor Symp Quant Biol 73:461-467, 2008.

Kuo M-L, den Besten W, Thomas MC, Sherr CJ. Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle 7: 3378-3387, 2008.

Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL(+), Arf-null lymphoblastic leukemia. Genes Dev 21: 2283-2287, 2007.

Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673, 2006.

Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103: 6688-6693, 2006.

Sherr CJ. Review: Principles of Tumor Suppression. Cell (30th Anniversary Issue) 116: 235-246, 2004.

Last update: May 2012